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Abstract
Background: The Rel/NF-kB transcription factors are often activated in solid or hematological malignancies. In most cases,
NF-kB activation is found in malignant cells and results from activation of the canonical NF-kB pathway, leading to RelA
and/or c-Rel activation. Recently, NF-kB activity in inflammatory cells infiltrating solid tumors has been shown to contribute
to solid tumor initiation and progression. Noncanonical NF-kB activation, which leads to RelB activation, has also been
reported in breast carcinoma, prostate cancer, and lymphoid leukemia.
Methodology/Principal Findings: Here we report a novel role for RelB in stromal cells that promote T-cell leukemogenesis.
RelB deficiency delayed leukemia onset in the TEL-JAK2 transgenic mouse model of human T acute lymphoblastic leukemia.
Bone marrow chimeric mouse experiments showed that RelB is not required in the hematopoietic compartment. In contrast,
RelB plays a role in radio-resistant stromal cells to accelerate leukemia onset and increase disease severity.
Conclusions/Significance: The present results are the first to uncover a role for RelB in the crosstalk between non-
hematopoietic stromal cells and leukemic cells. Thus, besides its previously reported role intrinsic to specific cancer cells, the
noncanonical NF-kB pathway may also play a pro-oncogenic role in cancer microenvironmental cells.
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Introduction
The Rel/NF-kB transcription factors function in multiple
biological processes, including development, immunity, inflamma-
tion, and response to cellular stress [1]. NF-kB subunits are often
activated in solid or hematological malignancies as the result of
rearrangements/mutations in their genes or in genes encoding
components of the NF-kB signaling pathway, persistent autocrine or
paracrine stimulation through specific cell surface receptors, or viral
or cellular oncoprotein activity (for review see [2,3]). NF-kB
activation in cancer cells has been shown to activate genes involved
in cell survival, proliferation, angiogenesis, invasion, and chemore-
sistance being therefore an important target for cancer therapy.
Recently,animportantfunctionforthe canonicalNF-kBp a t h w a yi n
inflammatory cells infiltrating several types of solid tumors has been
brought to light. NF-kB activation in those cells leads to the
production of cytokines, growth factors, and angiogenic factors that
promote malignant conversion and progression (for review see [3]).
The NF-kB proteins are transcriptional regulators that bind
cognate DNA elements as homo- or heterodimers. NF-kB activity
is controlled by interaction with IkB (inhibitor of NF-kB) proteins
and only when these are degraded by the proteasome, following
serine phosphorylation by IkB kinases (IKK) and ubiquitination,
are NF-kB dimers released. The NF-kB/Rel family comprises five
members (RelA, RelB, c-Rel, p50/p105, and p52/p100) sharing
the conserved Rel homology domain, which is responsible for
DNA binding, nuclear localization, dimerization, and IkB
binding. In contrast to RelA (p65), RelB, and c-Rel, the p50
and p52 proteins, which derive from proteolytic processing of the
p105 and p100 precursor proteins, respectively, lack transactiva-
tion domains. The p50 and p52 proteins act thus as transcriptional
repressors, except when forming heterodimers with other NF-kB
members or when interacting with other transcriptional activators,
such as the Bcl3 protein (for review see [1]).
Two main NF-kB activation pathways have been identified [1].
The canonical NF-kB activation pathway, which is triggered by an
array of stimuli such as proinflammatory cytokines, antigen
receptors, Toll-like receptors, and cellular stress, relies on IKKb
(IKK2)/IKKc (NEMO)-dependent IkB phosphorylation and
degradation and results in RelA and/or c-Rel activation.
Disruption of the canonical pathway in immune cells impairs
innate and acquired immune responses in a cell-autonomous or
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nical NF-kB activation pathway, which can be activated by
specific members of the TNF receptor family (e.g., lymphotoxin b
receptor [LTbR] and BAFF receptor [BAFF-R]) depends on
IKKa (IKK1) and NIK kinase activity but not on IKKb or IKKc
[1]. Upon stimulation, IKKa phosphorylates p100 on C-terminal
serine residues and induces its ubiquitin-dependent processing to
generate p52. When released from p100 sequestration, p52:RelB,
p50:RelB, and, as recently shown, p50:RelA dimers shuttle to the
nucleus to activate transcription of specific target genes [5–8].
Disruption of the noncanonical pathway also affects immune cell
function, impairing either lymphoid organogenesis due, at least in
part, to defective LTbR signaling, or mature B cell function and
maintenance due to defective BAFF-R signaling [9]. Furthermore,
inactivation of the noncanonical pathway breaks down central
tolerance as a result of impaired generation of medullary thymic
epithelial cells (mTEC), which are essential for negative selection
of autoreactive T cells [9–11].
Most studies in human lymphoid leukemia and lymphoma have
identifiedcanonicalNF-kBactivationinleukemiccells.Forexample,
NF-kB activation is frequently observed in Hodgkin’s lymphomas
due to activation of the CD30, CD40, and RANK receptors or due
to inactivating mutationsinthe IkBa-encoding gene [12]. Activation
of p50 homodimers and p50:RelA heterodimers was detected in all
major subtypes of human acute lymphoblastic leukemia (ALL) [13].
The v-rel oncogene, the retroviral counterpart of c-rel,i n d u c e s
aggressiveleukemia/lymphomainchickenandtransgenicmice[14].
Canonical NF-kB activity was also found in T-ALL induced in mice
following expression of a Tal1 transgene or of intracellular Notch1
(Notch1-IC) oncogenic protein [15,16]. Finally, both the canonical
and noncanonical NF-kB pathways were found to be activated by
viral oncoproteins,inparticular the HTLV1-encoded Taxprotein in
adult T-cell leukemia and the EBV-encoded LMP1 protein in B-cell
lymphoma [12].
Several reports indicate that the noncanonical NF-kB pathway
is also activated in specific subtypes of lymphoid leukemia and
lymphoma (for review see [9,12,17]). Chromosomal translocations
disrupting the Nfkb2 gene that generate truncated p100 proteins
and constitutive processing of p100 to p52 were identified in
cutaneous T-cell lymphoma, and, more rarely, in B-cell non-
Hodgkin lymphoma, chronic lymphocytic leukemia, and multiple
myeloma [9,12,17]. Transgenic expression of a truncated p100
protein led to the development of B-cell lymphomas in mice, thus
demonstrating the oncogenic potential of Nfkb2 mutations [18].
Recently, genetic alterations in components of the noncanonical
and canonical NF-kB pathways (e.g., NIK, TRAF3, CYLD, BIRC2/
BIRC3, CD40, NFKB1,o rNFKB2) resulting in their activation have
been identified in multiple myeloma [19,20].
In the present report we assessed the role of NF-kB proteins in a
transgenic mouse model for human T-ALL induced by the TEL-
JAK2 fusion protein [21,22] and uncovered a specific role for
RelB in T-cell leukemia development. Using RelB knockout mice
we found that RelB assisted TEL-JAK2-induced T-cell leukemo-
genesis. Interestingly, bone marrow chimeric mouse experiments
showed that RelB is not required in the hematopoietic
compartment but plays a role in radio-resistant stromal cells to
favor leukemia onset and increase disease severity.
Results
TEL-JAK2 leukemic cells display RelA and RelB activation
To assess the NF-kB activity status in leukemic T cells from
EmSRa-TEL-JAK2 transgenic mice, we performed electrophoretic
mobility shift assays (EMSA) on nuclear extracts using an NF-kB-
specific oligonucleotide probe. Nuclear extracts from TEL-JAK2
tumor cells showed significantly higher levels of NF-kB DNA-
binding activity, visible as two bands with different mobility, as
compared to control thymocyte nuclear extracts (Figure 1A). To
determine which NF-kB members were activated in TEL-JAK2
leukemic cells, we pre-incubated nuclear extracts with specific NF-
kB antibodies that either supershift or inhibit protein/DNA
complexes. A p50/NF-kB1 antibody quantitatively supershifted
band I and most of band II in TEL-JAK2 leukemic cells
(Figure 1B, compare lanes 1 and 2). The remaining NF-kB
activity in band II was inhibited by a p52/NF-kB2 antibody
(Figure 1B, lane 3), indicating the presence of both proteins in
different complexes. Band II complexes also included RelA and
RelB since the RelA antibody inhibited a slowly migrating
complex within band II (Figure 1C, lane 2 and Figure S1A, lane
3), leaving intact a faster migrating complex recognized by the
RelB antibody (Figure 1C, lanes 3 and 4 and Figure S1A, lane 4).
No c-Rel DNA-binding activity was found in TEL-JAK2 leukemic
cells (Figure S1A, lane 5), although this was easily detected in
thymocytes stimulated by phorbol 12-myristate 13-acetate (PMA)
plus ionomycin (Figure S1B, lane 4).
To identify the NF-kB dimers activated in TEL-JAK2 leukemic
cells, we performed supershift analyses combining different
antibodies. Combination of RelA and p50 antibodies yielded the
Figure 1. Activation of NF-kB transcription factors in TEL-JAK2
leukemic cells. (A) Nuclear extracts obtained either from freshly
isolated wild-type control thymocytes (WT thy) or from thymus (thy) or
lymph node (LN) leukemic cells from two representative TEL-JAK2 (TJ2)
diseased mice (nu66 and nu13) were analyzed by electrophoretic
mobility shift assays (EMSA) using the NF-kB-binding Ig-kB oligonucle-
otide probe. Similar results were obtained with more than 20 primary
leukemic samples. Bands labeled I and II (arrowheads) indicate specific
NF-kB complexes as assessed by competitive EMSA (data not shown).
An Ets-specific probe (E74) was used for nuclear extract normalization.
(B–D) Antibody supershift analysis of Ig-kB-bound complexes using the
indicated antibodies was performed on leukemic nuclear extracts from
individual TEL-JAK2 tumors (tumor nu1284 in panel B and D; tumor nu38
in panel C). Open arrows indicate supershifted complexes, filled arrows
identify the different NF-kB complexes, and the asterisk indicates a
nonspecific band. p50, p52, RelA, and RelB DNA-binding activity in TEL-
JAK2 leukemic cells was also detected using a palindromic NF-kB probe
derived from the IL2Ra promoter, indicating that the previous results
were not biased by differential DNA recognition by NF-kB proteins.
doi:10.1371/journal.pone.0002555.g001
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(Figure 1D, compare lanes 2 and 5), indicating that RelA
heterodimerized with p50. Combination of the RelB antibody
with p50 and RelA antibodies inhibited the remaining complex
(Figure 1D, compare lanes 5 and 6), which, given that RelB is
unable to form homodimers [23], corresponds to p52:RelB
heterodimers. Likewise, combination of the RelB antibody with
p52 and RelA antibodies inhibited a complex that corresponded to
p50:RelB heterodimers (Figure 1D, compare lanes 7 and 8). In
sum, supershift analyses discerned the presence of p50:p50
homodimers as well as p50:RelA, p50:RelB, and p52:RelB
heterodimers in TEL-JAK2 leukemic cells.
Nfkb1 deficiency does not affect TEL-JAK2-induced T-cell
leukemia development
To assess the role of NF-kB proteins in TEL-JAK2-induced
leukemogenesis, we bred EmSRa-TEL-JAK2 mice with mice
deficient for specific NF-kB genes. To prevent p50-containing
complex formation, we first bred EmSRa-TEL-JAK2 mice with
Nfkb1 knock-out mice, which do not express the NF-kB1 proteins
p50 and its precursor p105 and do not show any thymocyte
maturation defects [24]. EmSRa-TEL-JAK2;Nfkb1
2/2 and
EmSRa-TEL-JAK2;Nfkb1
+/2 littermate mice developed T-cell
leukemia with full penetrance and similar latency (Figure 2A;
median survival of 12 weeks). In addition, Nfkb1-deficient leukemic
cells presented a cell surface marker phenotype (expression of
variable levels of CD4, CD8, CD24, CD25, and TCRb/CD3e)
similar to that of Nfkb1-proficient cells (data not shown) and
characteristic of transgenic TEL-JAK2 leukemia [21,25].
EMSA analyses showed that the TEL-JAK2;Nfkb1
2/2 leukemic
cells displayed severely reduced NF-kB activity and, as expected, did
not display any p50 DNA-binding activity, as evidenced by the lack
of p50 homodimers (band I) (Figure 2B). Interestingly, no RelA
DNA-binding activity was detectable in nuclear extracts from TEL-
JAK2;Nfkb1
2/2 leukemic cells (Figure 2C). This was not due to an
intrinsic inability to activate RelA in these cells, since TEL-
JAK2;Nfkb1
2/2 leukemic cells induced p52:RelA and RelA:RelA
DNA-bound dimers upon in vitro treatment with PMA plus
ionomycin (Figure S2). This result suggests that activation of p50
and/or RelA does not play a nonredundant role in TEL-JAK2
leukemogenesis. The only DNA/protein complexes identified in
TEL-JAK2;Nfkb1
2/2 leukemic cells were p52:RelB heterodimers,
since formation of this complex was inhibited by antibodies against
either p52 or RelB, but not by p50-, c-Rel-, or RelA-specific
antibodies (Figure 2C and data not shown).
Generation of viable Relb-deficient mice
Since TEL-JAK2;Nfkb1
2/2 leukemic cells only presented
constitutive p52:RelB activity, we set out to evaluate the role of
RelB in TEL-JAK2-induced leukemogenesis by generating Relb-
deficient TEL-JAK2 transgenic mice. Relb-deficient mice present
fatal T-cell-dependent multiorgan inflammation, a phenotype
resulting from the absence of mTEC, which are essential for
negative selection of autoreactive T cells [26–28]. To generate
viable Relb-deficient mice, these were bred with Tcra-deficient
mice, which do not express the ab T-cell receptor (TCR) and
therefore lack mature T cells. The resultant Tcra
2/2;Relb
2/2 mice
were born at expected Mendelian ratios and lived without external
signs of inflammation or other abnormal phenotype, with the
exception that female mice failed to nurse their pups. Histological
analysis showed no inflammatory infiltrates in liver, lungs, and skin
of Tcra
2/2;Relb
2/2 mice (Figure S3A and data not shown),
demonstrating that Tcra deficiency rescued the inflammatory
phenotype observed in Relb-deficient mice [26–28]. In line with
previous findings [28], we observed that mature T-cell deficiency
in Relb-null mice prevented splenomegaly and splenic myeloid
hyperplasia (data not shown).
Relb-deficient mice present defective development of thymus and
secondary lymphoid organs [26,27,29]. The defective lymph node
development linked with RelB deficiency was not rescued by mature
T-cell deficiency (Figure S3B), showing that it is a non-T-cell-
dependent phenotype. In contrast, Tcra
2/2;Relb
2/2 mice presented
thymi of size similar to that of Tcra
2/2;Relb
+/+ littermates (data not
shown), confirming the notion that the severe thymic atrophyseen in
Relb-null mice is mainly due to T-cell dependent multiorgan
inflammation [30]. In contrast to wild-type thymi, Tcra
2/2;Relb
+/+
thymi presented reduced and disorganized medulla with few
scattered Ulex europaeus agglutinin 1 (UEA-1)-positive mTECs
(Figure 3A), a phenotype caused by the absence of mature T-cell
crosstalk with thethymicstroma[11,31,32].Tcra
2/2;Relb
2/2 thymi,
likeRelb
2/2 thymi[26,27,31],lackeddistinctivemedullaand did not
present any UEA-1
+ mTECs (Figure 3A). Despite a 1.4-fold
reduction in thymocyte cellularity in Tcra
2/2;Relb
2/2 mice as
compared to Tcra
2/2;Relb
+/2 mice (Figure 3B), early thymocyte
development proceeded similarly in both Relb-deficient and Relb-
proficient mice. Indeed, both groups of mice presented similar
Figure 2. Nfkb1 deficiency did not impair TEL-JAK2-induced T-cell leukemogenesis. (A) Kaplan-Meier leukemia-free survival curves for
EmSRa-TEL-JAK2 transgenic mice deficient or not for the Nfkb1 gene. No statistically significant differences were observed. The number of mice in
each group is given between parentheses. (B) Leukemic cell nuclear extracts from representative TEL-JAK2;Nfkb1
+/2 (mice nu110 and nu121) and TEL-
JAK2;Nfkb1
2/2 (mice nu109 and nu140) mice were analyzed by EMSA using the Ig-kB and Sp1 probes. I and II indicate specific DNA-bound NF-kB
complexes. Note the absence of band I (p50 homodimers) in Nfkb1
2/2 samples. (C) Antibody supershift analysis using the indicated antibodies on Ig-
kB-bound complexes derived from representative TEL-JAK2;Nfkb1
2/2 (mouse nu140) leukemic cells. Band II corresponds to p52/RelB DNA-bound
heterodimers. The asterisk indicates a non NF-kB-specific band.
doi:10.1371/journal.pone.0002555.g002
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2CD8
2 double negative (DN), CD8 immature
single positive, and CD4
+CD8
+ double positive (DP) thymocytes
(Figure 3C and data not shown). As expected, due to the Tcra
mutation no CD4 and CD8 single-positive (SP) cells were observed
in the two groups of mice. The proportion of DN subsets, as defined
by CD25 and CD44 expression, and TCRcd T-cell development
was also unaffected by RelB deficiency in Tcra
2/2;Relb
2/2 mice
(Figure 3C and Figure S4).
Relb deficiency delays the onset of TEL-JAK2-induced T-
cell leukemia
Our previous studies have shown that breeding of TEL-JAK2
transgenic mice on a Tcra-deficient background does not delay
leukemia onset and incidence [25], although TEL-JAK2;Tcra
2/2
leukemic cells showed reduced RelA DNA-binding activity as
compared to Tcra-proficient leukemic cells while maintaining a
similar level of RelB DNA binding activity (Figure S5). In contrast,
when EmSRa-TEL-JAK2 mice were bred on a Tcra
2/2;Relb
2/2
background, we found that these mice developed T-cell leukemia
with statistically significant delayed onset as compared to TEL-
JAK2;Tcra
2/2;Relb
+/+ littermates (median survival of 18.5 and 13
weeks, respectively; P,0.01) (Figure 4A). Diseased mice from both
groups presented leukemic cells in thymus, spleen, lymph nodes,
bone marrow, liver, and lungs (Figure S6 and data not shown).
However, TEL-JAK2;Tcra
2/2;Relb
2/2 mice presented significant-
ly reduced tumor load in thymus and lymph nodes, as compared
to Relb-proficient littermates (Figure 4B). Similar to Relb-proficient
cells, Relb-deficient leukemic cells presented the variable levels of
CD4, CD8, CD24, and CD25 cell surface markers that
characterize TEL-JAK2 leukemic cells (Figure S7). TEL-JAK2;T-
cra
2/2;Relb
2/2 leukemiccellsshowedsimilarp50:p50and p50:RelA
NF-kB DNA-binding activity as TEL-JAK2;Tcra
2/2;Relb
+/2 leuke-
mic cells (data not shown), indicating that RelB inactivation did not
lead to selection of leukemic cells displaying enhanced DNA-binding
activity of other NF-kB family members. Together, these results
reveal a non-redundant function for RelB in TEL-JAK2-induced
leukemogenesis. However, because RelB deficiency affects all mouse
tissues, these results do not distinguish whether RelB function is
required intrinsically in the hematopoietic cells targeted by TEL-
JAK2, and/or whether it is required in non-leukemic cells from the
tumor microenvironment to support TEL-JAK2-induced leukemo-
genesis.
Relb deficiency in the hematopoietic compartment does
not affect TEL-JAK2-induced T-cell leukemogenesis
To analyze whether the function of RelB in TEL-JAK2-induced
leukemogenesis reflected an intrinsic role in the hematopoietic
compartment, we generated bone marrow radiation chimeric mice.
Bone marrow cells obtained from either TEL-JAK2;Tcra
2/2;
Relb
2/2 or TEL-JAK2;Tcra
2/2;Relb
+/2 non-diseased mice were
intravenously injected into wild-type (WT), lethally irradiated
recipient mice (Figure 5A). Both groups of bone marrow chimeric
mice developed T-cell leukemia with similar onset (median survival
of 18 and 17 weeks for TEL-JAK2;Tcra
2/2;Relb
+/2RWT and
TEL-JAK2;Tcra
2/2;Relb
2/2RWT mice, respectively) (Figure 5B).
Diseased chimeric mice of both groups developed leukemia affecting
the thymus, frequently in association with pleural effusion, lymph
nodes, bone marrow, and occasionally spleen and liver (data not
shown). No significant difference in lymphoid organ invasion and
leukemic cell surface marker expression was observed between the
two experimental groups (Figure S8 and data not shown). Of note,
under these experimental conditions non-TEL-JAK2 transgenic
Tcra
2/2;Relb
2/2 and Tcra
2/2;Relb
+/2 bone marrow donor cells
Figure 3. Tcra;Relb double deficient mice present defective
thymic microarchitecturewithout impairmentofdoublepositive
thymocyte development. (A) Thymi from mice with the indicated
genotypes were stained by H&E (panels a–c) or with UEA-1 lectin, a cell
surface marker of medullary thymic epithelial cells (d–f). Note the clear
distinction between medulla (M) and cortex (C) in the wild-type thymus.
(B) Thymocyte total cell counts were plotted for Tcra
2/2;Relb
+/2 (n=7)
and Tcra
2/2;Relb
2/2 (n=8) mice aged from 12–16 weeks. (C) CD4, CD8
cell surface immunostaining of total thymocytes (top panels) and CD25,
CD44 staining of Thy1.2
+, CD4/CD8 double negative cells (bottom panels)
of representative mice of the indicated genotypes.
doi:10.1371/journal.pone.0002555.g003
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when adoptively transferred into lethally irradiated syngeneic WT
mice, as demonstrated by the similar proportions of DN and DP
thymocytes and by the absence of mature CD4 or CD8 SP cells
(Figure S9). Together, these results indicate that Relb deficiency in
the hematopoietic compartment hampered neither normal T-cell
development nor TEL-JAK2-induced T-cell leukemogenesis.
Relb deficiency in radiation-resistant non-hematopoietic
cells delays the onset of TEL-JAK2-induced T-cell
leukemia
Since RelB is expressed in thymic and lymph node non-
hematopoietic cells and since genetic experiments have shown that
RelB plays an important role in shaping thymus and lymph node
architecture during mouse development [26,27,33], we analyzed
whether RelB could play a role in leukemogenesis through a
hematopoietic cell-extrinsic mechanism. First, we assessed the ability
of Tcra
2/2;Relb
2/2 mice cells to support normal development of
Relb
+/+ T cells. Therefore, Tcra
2/2;Relb
+/+ bone marrow cells were
adoptively transferred into lethally irradiated Tcra
2/2;Relb
2/2
(Tcra
2/2RTcra
2/2;Relb
2/2)o rTcra
2/2;Relb
+/2 (Tcra
2/2R
Tcra
2/2;Relb
+/2) recipient mice. Expression of CD4, CD8, CD25,
and CD44 showed that both groups of chimeric mice presented
normal DN and DP thymocyte development (Figure S10A). No
significant difference in thymocyte cellularity was observed between
Tcra
2/2RTcra
2/2;Relb
2/2 and Tcra
2/2RTcra
2/2;Relb
+/2 mice
(data not shown). In these experiments, donor female Tcra
2/2 bone
marrow cells were adoptively transferred to male recipients, so
efficient thymusreconstitution by donorcells could beascertained by
the presence of X-chromosome-specific genomic sequences, as
detected by PCR, and the absence of Y-chromosome-specific
sequencesinthymocytesfromchimericrecipientmice(FigureS10B).
These results indicate that Tcra and Relb double deficiency in non-
hematopoietic cells does not impair the development of DN and DP
thymocytes, the T-cell compartment targeted by TEL-JAK2 in
leukemogenesis [25]. Thus, bone marrow cells from non-diseased
EmSRa-TEL-JAK2;Tcra
2/2 mice were intravenously injected into
lethally irradiated Tcra
2/2;Relb
2/2 and Tcra
2/2;Relb
+/+ littermate
recipient mice(Figure 6A).Wefound thatTcra
2/2;Relb
2/2 recipient
mice reconstituted with TEL-JAK2;Tcra
2/2 bone marrow cells
(TEL-JAK2;Tcra
2/2RTcra
2/2;Relb
2/2) developed T-cell leukemia
withdelayedonset,ascomparedtothereconstitutedTcra
2/2;Relb
+/+
littermates (TEL-JAK2;Tcra
2/2RTcra
2/2;Relb
+/+) (median survival
of 46 and 23 weeks, respectively; P,0.01; Figure 6B). Two TEL-
JAK2;Tcra
2/2RTcra
2/2;Relb
2/2 mice even survived without
leukemia for more than 60 weeks after transplantation (Figure 6B).
PCR detection of the TEL-JAK2 transgene and the wild-type Relb
allele in thymocytes from these mice showed effective donor bone
marrow engraftment (data not shown). The two groups of mice
developed severe dyspnea due to leukemic cell accumulation in the
thymus and to pleural effusion containing leukemic cells (data not
shown). Like the original TEL-JAK2 transgenic mice [21], diseased
chimeric mice showed leukemic cell accumulation in the bone
marrow, spleen, lungs, and liver (data not shown). Leukemic cells
from both groups of mice expressed variable levels of CD4, CD8,
Figure 4. Relb deficiency delays the onset of TEL-JAK2-induced T-cell leukemia. (A) Kaplan-Meier leukemia-free survival curves for EmSRa-
TEL-JAK2;Tcra
2/2 transgenic mice deficient or not for the Relb gene are significantly different (log-rank test, P value,0.01). The number of mice in
each group is given between parentheses. (B) Thymus and lymph node weights were plotted for leukemic Relb
+/+ and Relb
2/2 TEL-JAK2;Tcra
2/2
mice. **, P value,0.01; ***, P value,0.001 (unpaired t-test). The number of mice analyzed is given between parentheses.
doi:10.1371/journal.pone.0002555.g004
Figure 5. Relb deficiency in bone-marrow-derived hematopoi-
etic cells does not affect the onset of TEL-JAK2-induced
leukemia. (A) Schematic representation of the bone marrow adoptive
transfer approach used to generate TEL-JAK2 transgenic mice lacking
Relb in the hematopoietic compartment only. (B) Kaplan-Meier
leukemia-free survival curves for wild-type (WT) recipient mice that
received bone marrow from EmSRa-TEL-JAK2;Tcra
2/2 transgenic mice
deficient or not for the Relb gene (3 donors of each genotype) show no
statistically significant difference in survival. The number of mice
analyzed in each group is given between parentheses.
doi:10.1371/journal.pone.0002555.g005
RelB Promotes Leukemogenesis
PLoS ONE | www.plosone.org 5 July 2008 | Volume 3 | Issue 7 | e2555CD24, and CD25 cell surface markers, characteristic of bona fide
TEL-JAK2 T-cell leukemia (data not shown). However, in addition
to a delayed onset, TEL-JAK2;Tcra
2/2RTcra
2/2;Relb
2/2 diseased
mice presented significantly reduced accumulation of leukemic cells
in the thymus and lymph nodes, as compared to TEL-JAK2;
Tcra
2/2RTcra
2/2;Relb
+/+ mice (Figure 6C), indicating that the
disease evolved more slowly in lymphoid organs from Relb-deficient
chimeras. A similar difference in tumor burden was observed in
an independent experiment comparing leukemia development
between Tcra
2/2;Relb
2/2 and Tcra
2/2;Relb
+/2 recipients (Figure
S11). Taken together, these results show that RelB has a specific,
non-redundant function in radiation-resistant thymic and lymph
node stromal cells that facilitates TEL-JAK2-induced T-cell
leukemogenesis.
Discussion
In the present study we have found that expression of the RelB
transcription factor in non-hematopoietic, stromal cells promotes
T-cell leukemogenesis induced by the TEL-JAK2 oncoprotein.
These conclusions stem from two sets of data showing delayed
leukemia onset in (i) TEL-JAK2 transgenic mice deficient in RelB,
as compared to RelB-proficient littermates, and (ii) lethally
irradiated RelB-deficient mice reconstituted with TEL-JAK2
transgenic bone marrow, as compared to similarly reconstituted
RelB-proficient littermates. These results thus demonstrate that, in
addition to their reported pro-oncogenic role intrinsic to leukemic
cells in several mouse models [16,34] and in human leukemia cell
lines [12], NF-kB transcription factors contribute to T-cell
leukemogenesis through the generation and/or maintenance of a
proper stromal microenvironment.
Relb
2/2 mice develop lethal multiorgan inflammation shortly
after birth [26,27]. This disease is caused by the appearance of
autoreactive mature T cells resulting from the absence of mTECs
expressing Aire transcriptional regulator-dependent peripheral
tissue antigens, which are important to establish central self-
tolerance [26–28,35]. The possibility that the delay in TEL-JAK2-
induced leukemogenesis observed in RelB-deficient mice could be
linked to the inflammatory phenotype of these mice can be
excluded since our experiments were performed in the Tcra
2/2
genetic background, which prevents the development of autore-
active T cells. Indeed, in contrast to the reported RelB-deficient
phenotype [26–28], no significant inflammatory infiltrates were
observed in the organs of Tcra
2/2;Relb
2/2 mice.
Our previous results showed that TEL-JAK2 transforms
immature DN and DP thymocytes [25]. Since DN and DP
thymocyte development remained unaffected in the Tcra
2/2;
Relb
2/2 thymic microenvironment, we exclude the possibility that
the delay in TEL-JAK2-induced leukemogenesis in RelB-deficient
mice was simply due to a reduction in cellular targets available for
oncogenic transformation. Our results thus suggest that the RelB-
dependent microenvironment contributes specifically to DN/DP
thymocyte transformation by TEL-JAK2.
Mouse RelB deficiency results in impaired lymphoid organ
microarchitecture, affecting to varying degrees the development of
thymus, spleen, lymph nodes, and Peyer’s patches [26,27,33].
Stromal defects in these lymphoid organs likely account for the
observed delay in TEL-JAK2-induced leukemogenesis in Tcra
2/2;
Relb
2/2 mice. Since RelB-deficient diseased mice (both TEL-
JAK2;Tcra
2/2;Relb
2/2mice and TEL-JAK2;Tcra
2/2RTcra
2/2;
Relb
2/2 chimeric mice) presented reduced thymic and lymph node
tumor load compared to RelB-proficient controls, we conclude
that defects in these organs were responsible for the delay in
leukemogenesis.
Although lymph node development is strongly affected by the lack
of RelB, the direct cellular defects associated with RelB deficiency in
this organ are as yet unknown. In contrast, it has been shown that
RelB-deficientthymilacka definedmedulla and mTECs and show a
strong reduction in CD80
+DEC205
+ dendritic cell (DC) numbers
secondary to the defect in thymic architecture and mTECs
[26,27,36]. Accordingly, Tcra
2/2;Relb
2/2 mice showed no discern-
able thymic medulla and no UEA-1
+ mTECs. TCRa-deficient mice
also show thymic architectural defects, with reduced and disorga-
nized medulla and fewer UEA-1
+ mTECs than wild-type mice
[11,31,32]. These defects are restored by adoptive transfer of mature
T cells [11]. The combined deficiency of Tcra and Relb,b u tn o tTcra
deficiency alone [25], delayed TEL-JAK2-induced leukemia onset,
thus indicating that, contrary to the RelB-deficient thymic defects,
those found in TCRa-deficient mice have no detectable impact on
leukemia development. Gray et al [31] have recently shown that
TCRa-deficient thymi lack MHC II
lo/Ly51
2 (mTEC
lo)c e l l s ,w h i l e
Figure 6. Relb deficiency in radiation-resistant non-hematopoietic cells delays the onset of TEL-JAK2-induced T-cell leukemia. (A)
Schematic representation of the bone marrow adoptive transfer approach used to generate TEL-JAK2 transgenic mice lacking Relb in non-
hematopoietic cells only. (B) Kaplan-Meier leukemia-free survival curves for Tcra
2/2 recipient mice deficient or not for the Relb gene that received
bone marrow from EmSRa-TEL-JAK2;Tcra
2/2 transgenic mice were significantly different (log-rank test, P value,0.01). A mouse deceased from an
unrelated cause was censored in the analysis (tick mark). (C) Thymus and lymph node weights were plotted for TEL-JAK2;Tcra
2/2RTcra
2/2;Relb
2/2
and TEL-JAK2;Tcra
2/2RTcra
2/2;Relb
+/+ diseased chimeric mice. *, P value,0.05; ***, P value,0.001 (unpaired t-test). The number of mice analyzed in
each group is given between parentheses.
doi:10.1371/journal.pone.0002555.g006
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hi/Ly51
2 (mTEC
hi)
cells. It is thus tempting to speculate that specifically mTEC
hi cells
assist TEL-JAK2-induced T-cell leukemogenesis, although we
cannot exclude an additional requirement for a RelB-dependent
function in other stromal cells including DCs or cortical thymic
epithelial cells. Moreover, RelB-dependent thymic stromal cells may
assist TEL-JAK2 leukemogenesis either directly, through cell-cell
contact or paracrine growth factor stimulation, or indirectly by
stimulating other stromal cells (e.g., DCs) to interact with leukemic
cells.
The nature of the molecular signals emanating from the thymic
or lymph node stroma that favor T-cell leukemia initiation or
progression remains to be identified. It is likely that RelB activity
in mTEC or lymphoid organ stromal cells induces the expression
of genes that favor T-cell leukemogenesis. Proteins known to play a
role in thymic function include cytokine/growth factors (e.g., IL-7,
Kit ligand, Notch ligands, and Sonic Hedgehog), chemokines (e.g.,
Ccl19/Elc, Ccl21/Slc, Ccl25/Teck, and Cxcl12/Sdf-1), cell
surface receptors (e.g., LTbR, RANK, and Notch-1 to -3) and
adhesion molecules (e.g., ICAM-1, MAdCAM-1, and VCAM-1)
[37,38]. RelB DNA-binding activity can be stimulated by RANK
and LTbR, two receptors coupled to NF-kB activation and shown
to be important for thymic medulla and lymphoid organ formation
[39]. Both receptors activate NF-kB through the canonical and
noncanonical pathways, with RANK specifically requiring
TRAF6. LTbR signaling in thymic mTECs and in lymph node
DCs induces expression of Ccl19 and Ccl21 [40,41], which are
known RelB target genes [42,43], and of these chemokines as well
as MAdCAM1, ICAM-1, and VCAM-1 in lymph node stromal
cell organizers [44]. Since TEL-JAK2 leukemic cells express the
Ccr7 transcript, encoding the receptor for the Ccl19 and Ccl21
chemokines (data not shown), and display cell surface expression of
the ICAM-1 receptor LFA-1 (data not shown), it is tempting to
speculate that these NF-kB signaling-dependent targets may play a
role in TEL-JAK2-induced leukemogenesis.
Recent studies have shown that the composition of the thymic
stroma is dynamic and modulated by particular stimuli (e.g.,
LTab, FGF family members, Wnt, and steroids) [45]. It is thus
possible that leukemic T cells analogously induce qualitative and/
or quantitative changes in thymic stromal populations. Our
transcriptomic analysis showed higher expression levels of the
LTa- and LTb-encoding genes in TEL-JAK2 leukemic cells as
compared to normal thymocytes ([25] and data not shown). It is
therefore possible that LTa1b2 production by leukemic cells may
modulate the thymic microenvironment in its favor through
interaction with LTbR-expressing stromal cells and in this way
contribute to leukemogenesis.
Our data cannot discriminate whether RelB-dependent stromal
cells facilitate the initiation or the progression of T-cell leukemia,
or both. Nevertheless, the limited tumor burden in thymus and
lymph nodes of terminally ill TEL-JAK2;Tcra
2/2;Relb
2/2 and
TEL-JAK2;Tcra
2/2RTcra
2/2;Relb
2/2 mice suggests that the
RelB-dependent thymic microenvironment favors the expansion
of transformed leukemic cells. During normal T-cell development,
Tcra
2/2;Relb
2/2 thymi presented a slight reduction in thymocyte
cellularity as compared to Tcra
2/2;Relb
+/2 thymi, suggesting that
both normal and leukemic T cell expansion is affected by RelB-
dependent thymic stroma. The thymic medulla is a compartment
where IL-7-dependent proliferation of mature T cells occurs
before their export to the periphery [46,47]. This compartment in
RelB-proficient TEL-JAK2 mice could favor the expansion of
leukemic cells in the thymus.
Stromal cells from lymphoid organs or from the bone marrow are
important to sustain survival and proliferation of human leukemic
cells. The survival of T-ALL primary cells in vitro is promoted by
exogenous growth factors (e.g., IL-7) or by co-culture with bone
marrow or thymic stromal cells [48–51]. Also, thymectomy was
shown to prevent T-cell leukemia development induced by Ikaros
deficiency in mice [52], further supporting an important role of the
thymic microenvironment in T-cell leukemia development. That
tumor microenvironmental-derived signals are required for the in
vivo expansion of TEL-JAK2-induced leukemic cells is supported by
the fact that these cells survived for over a week ex vivo but failed to
proliferate under these conditions (data not shown).
TEL-JAK2 leukemic cells displayed NF-kB activity (p50, p52,
RelA, and RelB), suggesting that, in addition to a noncell-
autonomous role, NF-kB activation may also contribute cell-
autonomously to TEL-JAK2 leukemia development or mainte-
nance. Intrinsic canonical NF-kB activity has recently been shown
to be important for Notch-induced murine T-cell leukemia, since
disease development was inhibited by expression of the IkBa
super-repressor mutant [16,34]. This effect could be specific to
these particular models of T-cell leukemia, since the IkBa super-
repressor failed to affect Tal-1-induced T-ALL [15]. Transgenic
co-expression of the IkBa super-repressor with TEL-JAK2 neither
did inhibit NF-kB activity nor affected leukemia incidence or
severity (N.d.S., Marie Ko ¨rner, and J.G., unpublished data).
Likewise, Nfkb1 deficiency failed to affect TEL-JAK2-induced
leukemogenesis. Interestingly, TEL-JAK2;Nfkb1
2/2 leukemic cells
did not present any RelA DNA-binding activity. In addition, RelA
DNA-binding activity was reduced in TEL-JAK2;Tcra
2/2 com-
pared to TEL-JAK2;Tcra
+/2 leukemic cells. These observations
together with the fact that TCRa-deficiency did not affect TEL-
JAK2 leukemia onset [25], indicates that RelA DNA-binding
activity correlates neither with leukemia time of onset nor with
disease progression. In addition, bone marrow adoptive transfer
experiments showed that RelB deficiency in hematopoietic cells
did not affect TEL-JAK2-induced leukemogenesis. These results
indicate that cell-autonomous RelB expression is not essential for
TEL-JAK2 leukemia initiation or maintenance. However, since
NF-kB functional redundancy may exist among the different
members of the NF-kB family and since complete NF-kB
activation could not be experimentally achieved in TEL-JAK2
leukemic cells, we cannot rule out that NF-kB plays a cell-
autonomous role, in addition to a non-cell-autonomous role, in
TEL-JAK2-induced leukemogenesis.
The p52 and RelB proteins are activated by the noncanonical
NF-kB activation pathway, which depends on NIK/IKKa-
induced p100 processing. Accumulating evidence shows that the
noncanonical NF-kB pathway is activated in the tumor cells of
several human cancers, including B- and T-cell leukemia/
lymphoma, mammary carcinoma, and prostate cancer
[12,17,19,20,43,53,54]. The present results are however the first
to uncover a role for RelB in the crosstalk between stromal and
leukemic cells. Thus, the noncanonical NF-kB pathway may play
a pro-oncogenic role both in tumor cells and in cells that compose
the tumor microenvironment. In other settings, this property is
shared by the canonical NF-kB activity which also plays an
important role in activating both intrinsic genetic programs in
cancer cells and the production of pro-oncogenic growth factors in
cancer-associated stromal or inflammatory cells [3]. It will thus be
important to understand how the thymic or lymphoid organ
microenvironment assists T-cell leukemia development and to
identify the leukemia-promoting factors that are dependent on
noncanonical NF-kB activity in stromal cells. A better under-
standing of the crosstalk between leukemic T cells and stromal cells
may pave the way for the development of new therapeutic
strategies targeting this disease.
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Mice
The EmSRa-TEL-JAK2 transgenic mice (line 71) [21] were bred
with Tcra (obtained from CNRS-CDTA; Orle ´ans, France), Relb [27],
and Nfkb1 [24] knock-out mice on the C57BL/6 background. All
mice were maintained under specific-pathogen-free conditions in the
animal facility of the Institut Curie (Orsay, France). All experimental
procedures were performed in strict accordance with the recom-
mendations of the European Community (86/609/EEC) and the
French National Committee (87/848) for the care and use of
laboratory animals. All animal experiments were carried out under
the supervision of J.G., who was authorized by the director of the
Veterinary Services of the Pre ´fecture de l’Essonne (agreement
number 91-7). TEL-JAK2 transgenic mice were euthanized when
terminally ill, due to either severe dyspnea caused by massive
expansion of leukemic cells in the thymus or extreme weakness
caused by leukemic dissemination to vital organs such as bone
marrow, lung, and liver. Statistical analyses and survival curves were
calculatedusingPrism4(GraphPad,SanDiego,CA).GenomicPCR
of the sex chromosome-localized Jarid1c/Kdm5c and Jarid1d/Kdm5d
genes was performed as described by Clapcote and Roder [55].
Bone marrow adoptive transfer experiments
Mouse bone marrow cells (BMC) were flushed out from hind
legs. TEL-JAK transgenic BMC were obtained from nondiseased
4-week-old mice, as verified by the absence of leukemic cells
(CD4
+CD8
+CD25
+) in the thymus and bone marrow by flow
cytometry. In adoptive transfer experiments, 2–3610
6 BMC were
intravenously injected into lethally irradiated (8.125 Gy) mice
using an IBL-637 (
137Cs) c-irradiator (CIS-BioInternational,
Saclay, France).
Cell isolation and culture
Single cell suspensions were prepared from lymphoid organs
gently dissociated and filtered through 70-mm cell strainers. To
determine thymocyte cellularity, Trypan Blue (Sigma-Aldrich, St.
Louis, MO)-negative viable cells were counted on KOVA
microscope slides (Hycor Biomedical, Garden Grove, CA). For
in vitro stimulation, cells were cultured at 37uCa t5 610
6 cells/ml
in RPMI 1640 (Invitrogen, Carlsbad, CA), 5% heat-inactivated
FBS (Invitrogen), 50 mM b-mercaptoethanol (Sigma-Aldrich) and
stimulated with PMA and ionomycin (both from Sigma-Aldrich) at
the indicated concentrations for the indicated period of time.
Nuclear extract preparation and electrophoretic mobility
shift assays (EMSA)
Thymocyte and leukemic cell nuclear extracts were prepared as
described by Olnes and Kurl [56]. Briefly, 5610
7 cells were
resuspended in 500 ml lysis buffer (10 mM Hepes [pH 7.9],
10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, and 1 mM DTT)
with protease and phosphatase inhibitors (1 mM phenylmethyl-
sulphonylfluoride, 15 mg/ml aprotinin, 10 mg/ml leupeptin,
1m MN a 3VO4,1 5m Mb-glycerolphosphate, and 10 mM para-
nitrophenylphosphate; all from Sigma-Aldrich), rested for 10 min
on ice, and lyzed using a Dounce homogenizer (25 strokes with a
tight pestle) (Wheaton, Millville, NJ). The cellular lysate was
pelleted at 110g, the supernatant removed, and nuclei were lyzed
in 100 ml of extraction buffer (20 mM Hepes [pH 7.9], 400 mM
NaCl, 1 mM EDTA, 1 mM EGTA, 10% glycerol, and 1 mM
DTT) and protease and phosphatase inhibitors. The nuclear
extracts were collected after centrifugation at 20,000g. EMSA were
performed essentially as described [57], using Klenow polymerase
(New England Biolabs, Ipswich, MA) end-labeled double-stranded
oligonucleotide probes containing the Ig-kB NF-kB-binding site
(plus strand: 59-CAGAGGGGACTTTCCGAGAGG-39) [58], the
IL2Ra promoter palindromic NF-kB site (plus strand: 59-TTGG-
CAACGGCAGGGGAATTCCCCTCTCCTTA-39) [59], and
Sp1-binding site (plus strand: 59-ATTCGATCGGGGCGGGGC-
GAGC-39). DNA binding reactions were carried out for 10 min at
0uC in a final volume of 16 ml containing 1 ng (,125 fmol) of
oligonucleotide probe, 10 mM HEPES [pH 7.4], 25 mM KCl,
1.25 mM Na phosphate, 175 mM EDTA, 75 mM EGTA, 1 mM
DTT, 5 mM MgCl2, 1.5 mg poly[d(I-C)], 0.4 mg salmon sperm
DNA and 1–5 mg nuclear extracts. For supershift analyses,
polyclonal antibodies against p50 (nu71 and nu1263; kindly
provided by John Hiscott and Nancy Rice, respectively), p52
(nu1495; kindly provided by Nancy Rice), and RelA (sc-109), RelB
(sc-226), and c-Rel (sc-71) from Santa Cruz Biotechnology (Santa
Cruz, CA) were incubated with binding reactions for 10 min on
ice before electrophoresis.
Flow cytometry
Single cell suspensions from lymphoid organs were stained with
fluorochrome-labeled antibodies and detected by a FACSCalibur
cytometer (BD Biosciences, San Jose, CA) as previously described
[21]. Fluorescein isothiocyanate (FITC)-, R-phycoerythrin (PE)-,
PE-cyanine 5 (PE-Cy5)- or allophycocyanin (APC)-conjugated
antibodies specific for CD90.2/Thy1.2 (53-2.1) CD4 (H129.19),
CD8a (53-6.7), CD3e (145-2C11), TCRb (H57-597), TCRcd
(GL3), CD5 (53-7.3), CD24/HSA (M1/69), and CD25/IL-2Ra
(7D4) (BD Biosciences) were used. The data were analyzed using
CellQuest (BD Biosciences) and FlowJo (Tree Star, Ashland, OR).
Histopathological and immunohistochemical analyses
Histopathological analyses were performed essentially as
previously described [21]. For immunohistochemistry, 6-mm
formalin-fixed, paraffin-embedded, thymus sections were depar-
affinized and hydrated. After each of the following incubations the
slides were rinsed with several changes of PBS. Sections were
blocked with 0.3% H2O2 in PBS for 15 min, followed by 0.5%
casein in PBS for 15 min and incubated with 1:50 biotinylated
UEA-1 lectin for 2 h at room temperature followed by ABC
peroxidase for 30 min. Sections were visualized by DAB staining,
counterstained with Meyers hematoxylin, dehydrated and mount-
ed in non-aqueous mounting media. All staining reagents were
obtained from Vector Labs (Burlingame, CA).
Supporting Information
Figure S1 TEL-JAK2 leukemic cells do not show c-Rel DNA-
binding activity. (A) NF-kB activity (bands I and II, indicated by
arrowheads) in nuclear extracts obtained from leukemic cells from
a representative TEL-JAK2 tumor (nu20) does not include c-Rel,
as shown by supershift analysis using the indicated antibodies. (B)
The same c-Rel antibody supershifted an NF-kB complex (open
arrowheads) in thymocytes stimulated for 24 h by 5 ng/ml PMA
plus 250 ng/ml ionomycin.
Found at: doi:10.1371/journal.pone.0002555.s001 (2.30 MB TIF)
Figure S2 TEL-JAK2;Nfkb1
2/2 leukemic cells activate RelA
when stimulated with PMA plus ionomycin. (A) TEL-
JAK2;Nfkb1
2/2 leukemic cells were stimulated for the indicated
period of time with 50 ng/ml PMA plus 500 ng/ml ionomycin and
nuclear extracts were analyzed by EMSA using the Ig-kB and Sp1
probes. (B) PMA plus ionomycin stimulation for 30 min induced
RelA and p52. RelA-containing complexes are indicated by arrows.
The p52:RelB complexes (band II) are shown by arrowheads.
Found at: doi:10.1371/journal.pone.0002555.s002 (2.26 MB TIF)
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2/2;Relb
2/2 and control
mice. (A) H&E staining of liver (a–c) and lung (d–f) from mice of
the indicated genotypes reveals an absence of inflammatory
infiltrates in Tcra
2/2;Relb
2/2 mice. (B) H&E staining of
mesenteric lymph nodes (a–c) from mice of the indicated
genotypes shows rudimentary lymph nodes in Relb-deficient mice,
as compared to Relb-proficient mice. Also note the presence of B-
cell follicles in RelB-proficient lymph nodes (arrowheads).
Found at: doi:10.1371/journal.pone.0002555.s003 (9.62 MB TIF)
Figure S4 TCRcd T cells develop normally in Tcra;Relb double
deficient thymi. TCRcd and CD5 cell surface immunostaining of
gated Thy1.2+, CD4/CD8 double negative cells of representative
mice of the indicated genotypes.
Found at: doi:10.1371/journal.pone.0002555.s004 (2.52 MB TIF)
Figure S5 NF-kB activity in TEL-JAK2 leukemic cells depends
on abTCR expression. (A) Leukemic cell nuclear extracts from
representative TEL-JAK2;Tcra
+/2 and TEL-JAK2;Tcra
2/2 mice
were analyzed by EMSA using the Ig-kB and Sp1 probes. (B)
Antibody supershift analysis of Ig-kB-bound complexes using the
indicated antibodies was performed on nuclear extracts from
representative TEL-JAK2;Tcra
2/2 leukemic cells. I and II indicate
migrating DNA-bound NF-kB complexes.
Found at: doi:10.1371/journal.pone.0002555.s005 (1.95 MB TIF)
Figure S6 Diseased Relb-deficient and Relb-proficient TEL-
JAK2 mice show similar macroscopic appearance. The thymus
(a,b), spleen (c,d), and lung (e,f) of a representative mouse of each
indicated genotype is shown. Note the massive invasion of the
organs by leukemic cells. Arrowheads indicate areas of leukemic
cell infiltration in the lungs.
Found at: doi:10.1371/journal.pone.0002555.s006 (6.72 MB TIF)
Figure S7 Relb-deficient and Relb-proficient TEL-JAK2 leuke-
mic cells present a similar cell surface marker phenotype. (a–f) Cell
surface staining with CD4 and CD8 antibodies of wild-type
thymocytes (a), two representative TEL-JAK2;Tcra
2/2;Relb
+/2
mice (b,c), and three representative TEL-JAK2;Tcra
2/2;Relb
2/2
mice (d–f). (g–j) Cell surface staining with CD24 or CD25
antibodies of two representative TEL-JAK2;Tcra
2/2;Relb
+/2 mice
(top panels), and three representative TEL-JAK2;Tcra
2/2;Relb
2/2
mice (bottom panels).
Found at: doi:10.1371/journal.pone.0002555.s007 (5.22 MB TIF)
Figure S8 Relb deficiency in the hematopoietic compartment does
not affect leukemic cell accumulation in lymphoid organs. Diseased
mice adoptively transferred with Relb-deficient TEL-JAK2;Tcra
2/2
bone marrow cells (TEL-JAK2;Tcra
2/2;Relb
2/2RWT) presented
lymphoid organ tumors of similar weight as mice transferred with
TEL-JAK2;Tcra
2/2;Relb
+/2 bone marrow (TEL-JAK2;Tcra
2/2;
Relb
+/2RWT). Thymus and lymph node weights were plotted for
each group mice. The number of analyzed mice is given between
parentheses.R
Found at: doi:10.1371/journal.pone.0002555.s008 (5.98 MB TIF)
Figure S9 Efficient thymocyte development in wild-type mice
adoptively transferred with either Tcra
2/2;Relb
+/2 or Tcra
2/2;
Relb
2/2 bone marrow cells. Top panels: CD4 and CD8
immunostaining shows a very low proportion of SP (host)
thymocytes in representative pairs of recipient wild-type (WT)
mice, indicating that the majority of thymocytes originated from
donor hematopoietic cells given that TCRa deficiency blocks DP
to SP transition. Bottom panels: CD25 and CD44 staining of gated
CD4/CD8 DN cells of representative WT mice reconstituted with
either Tcra
2/2;Relb
+/2 or Tcra
2/2;Relb
2/2 bone marrow. Note
that the RelB mutation does not significantly affect early
thymocyte development.
Found at: doi:10.1371/journal.pone.0002555.s009 (6.52 MB TIF)
Figure S10 Normal double negative and double positive
thymocyte development in bone marrow-reconstituted Tcra
2/2;
Relb
+/+ and Tcra
2/2;Relb
2/2 mice. (A) CD4, CD8 cell surface
immunostaining of total thymocytes (top panels) and CD25, CD44
staining of Thy1.2+, CD4/CD8 DN cells (bottom panels) of
representative pairs of Tcra
2/2RTcra
2/2;Relb
2/2 and Tcra
2/2R
Tcra
2/2;Relb
+/+ chimeric mice. (B) Thymocytes from chimeric
recipient male mice of the indicated genotypes that received bone
marrow cells from female Tcra
2/2 donors were analyzed by PCR
amplification of the Jarid1c/Kdm5c and Jarid1d/Kdm5d genes. The
upper band derived from the Jarid1c gene, located on the X
chromosome, while the lower band derived from the Jarid1d gene,
located on the Y chromosome [55]. Note the full reconstitution of
recipient male thymus with thymocytes of donor (female) origin.
Found at: doi:10.1371/journal.pone.0002555.s010 (5.88 MB TIF)
Figure S11 TEL-JAK2-induced T-cell lymphoid tumors are
smaller in Tcra
2/2;Relb
2/2 than Tcra
2/2;Relb
+/2 recipient mice.
(A) Kaplan-Meier leukemia-free survival curves for Tcra
2/2;
Relb
2/2 and Tcra
2/2;Relb
+/2 chimeric mice that received bone
marrow from EmSRa-TEL-JAK2;Tcra
2/2 transgenic mice (medi-
an survival of 211 and 164 days, respectively; log-rank test, P
value=0.1016). The number of mice in each group is given
between parentheses. (B) Thymus and lymph node weights were
plotted for TEL-JAK2;Tcra
2/2RTcra
2/2;Relb
2/2 and TEL-
JAK2;Tcra
2/2RTcra
2/2;Relb
+/2 chimeric mice that developed
T-cell leukemia/lymphoma. **, P value,0.01; ***, P value,0.001
(unpaired t-test). The number of mice analyzed is given between
parentheses.
Found at: doi:10.1371/journal.pone.0002555.s011 (5.41 MB TIF)
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